Bedrijfsoverzicht
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical enterprise dedicated to the development and commercialization of product candidates specifically designed for the treatment of central nervous system diseases. The company operates within the healthcare sector, functioning as a biotechnology firm that focuses on advancing novel therapies through rigorous clinical trial phases. As of the latest available data, the entity maintains a market capitalization of $238.44M and employs a workforce of 7 individuals. The market capitalization figure of $238.44M indicates that the company holds a mid-sized valuation within the biotechnology landscape, while the absence of reported annual revenue suggests the business is still in an early stage of development where capital allocation is primarily directed toward research and development rather than commercial sales. This operational scale reflects a typical profile for clinical-stage biopharmaceutical companies that are prioritizing the advancement of their lead product candidate, roluperidone, through Phase 3 confirmatory trials before seeking widespread market entry.
Financiële gezondheid
The financial statements for Minerva Neurosciences, Inc. report net income of $-293,423,168 over the trailing twelve months, while EBITDA stands at $-15,097,528 and revenue is not available for reporting. The significant disparity between the reported net income loss and the more modest EBITDA loss reveals a cost structure heavily burdened by substantial non-operating expenses or one-time charges that significantly depress the bottom line beyond core operational cash burn. The company generates free cash flow of $-8,543,694, which indicates a continuous cash outflow that limits immediate financial flexibility but is typical for biotechnology firms investing heavily in clinical trial infrastructure and patient recruitment. All three key margin metrics—the gross margin, operating margin, and profit margin—are reported at 0.0%, a figure that technically arises when revenue is not available or negligible, highlighting that the company is not yet generating sufficient commercial sales to establish meaningful profitability ratios. In terms of solvency, Minerva Neurosciences, Inc. holds cash reserves of $82.30M against total debt obligations of $60.00M, creating a net cash position that suggests a conservative balance sheet approach despite the absence of a calculated debt-to-equity ratio. The current ratio is reported at 36.28, an exceptionally high figure that indicates robust short-term liquidity and a substantial buffer of current assets available to cover current liabilities. Return on assets is recorded at -14.0%, reflecting the capital-intensive nature of the asset base relative to the negative earnings, while return on equity is not available due to the company's financial structure. These metrics collectively illustrate a firm that is currently consuming capital to achieve clinical milestones rather than generating returns on its invested equity or assets.
Waarderingsbeoordeling
Valuation multiples for Minerva Neurosciences, Inc. present a complex picture where the trailing P/E ratio is not available due to negative earnings, and the forward P/E ratio is calculated at -11.48, implying that expected future earnings remain negative in the near term. The price-to-book ratio is reported at -1.69, a negative figure that typically occurs when book value is adjusted for intangible assets or accumulated deficits, indicating that the market price does not reflect a traditional premium over tangible book value. Alternative valuation metrics such as the price-to-sales ratio are not available, and the EV/EBITDA stands at -14.64, suggesting that traditional enterprise value multiples are not applicable given the company's pre-revenue or micro-revenue status and negative cash flows. The stock has experienced significant volatility, trading within a 52-week range between a low of $1.30 and a high of $12.46. Without a specific current price provided in the source data to calculate the exact percentage deviation, the stock's position is defined by this wide historical band which captures the high risk associated with clinical-stage development. The beta coefficient is recorded at -0.21, a unique and highly unusual negative value that suggests the stock price historically moves in the opposite direction of the broader market or exhibits a volatility profile that is inversely correlated with market indices, though such metrics require careful interpretation in the context of small-cap biotechnology equities.
Growth & Income
Growth metrics for Minerva Neurosciences, Inc. show that revenue growth year-over-year is not available, and earnings growth year-over-year is also not available due to the company's current financial stage. The absence of positive earnings growth rates is consistent with a biotechnology company in the clinical phase that prioritizes reinvestment over profit expansion. Regarding income distribution, the dividend yield is not available, and the payout ratio is 0.0%, confirming that the company does not distribute dividends to shareholders. Instead of paying out income, the company retains its earnings and cash reserves to fund ongoing research, development, and the progression of its lead product candidate through Phase 3 trials. The overall growth and income profile is characterized by zero dividend income and a focus on capital preservation and clinical advancement rather than current shareholder yield.